marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Sonoma Pharmaceuticals Balance Sheet 2011-2024 | SNOA
Annual Balance Sheet Sonoma Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-2.84 M | -3.4 M | -6.84 M | -2.67 M | -2.21 M | -3.36 M | -9.8 M | -17.3 M | -7.36 M | -6.05 M | -5.33 M | -5.96 M | -112 K | -1.83 M |
Long Term Debt |
87 K | 162 K | 309 K | 1.31 M | - | 12 K | 32 K | 45 K | - | - | 4 K | 676 K | 1.82 M | 1.64 M |
Long Term Debt Current |
198 K | 256 K | 250 K | 240 K | 251 K | 497 K | 230 K | 123 K | 114 K | 87 K | 143 K | 1.26 M | 1.42 M | - |
Total Non Current Liabilities |
- | - | - | - | 991 K | 368 K | 619 K | 740 K | 112 K | 413 K | 1.16 M | 3.36 M | 3.96 M | 2.55 M |
Total Current Liabilities |
3.72 M | 3.72 M | 5.82 M | 4.08 M | 4.86 M | 3.59 M | 3.26 M | 3.29 M | 3.55 M | 2.58 M | 7.57 M | 5.13 M | 4.75 M | - |
Total Liabilities |
8.6 M | 8.25 M | 10.1 M | 9.62 M | 5.86 M | 3.96 M | 3.88 M | 4.03 M | 3.66 M | 2.99 M | 8.73 M | 8.48 M | 8.71 M | 6.96 M |
Deferred Revenue |
478 K | 160 K | 1.22 M | 267 K | 273 K | 102 K | 206 K | 521 K | 574 K | 769 K | 2.63 M | 2.32 M | 1.62 M | 1.81 M |
Retained Earnings |
-194 M | -190 M | -184 M | -179 M | -172 M | -169 M | -157 M | -143 M | -152 M | -142 M | -134 M | -138 M | -132 M | -125 M |
Total Assets |
14.7 M | 16.2 M | 18.8 M | 15 M | 14.6 M | 14.4 M | 19.2 M | 25.5 M | 13.8 M | 15 M | 20.8 M | 12.6 M | 7.84 M | 8.66 M |
Cash and Cash Equivalents |
3.13 M | 3.82 M | 7.4 M | 4.22 M | 3.69 M | 3.69 M | 10.1 M | 17.5 M | 7.47 M | 6.14 M | 5.48 M | 7.9 M | 3.35 M | 4.37 M |
Book Value |
6.14 M | 7.98 M | 8.7 M | 5.36 M | 8.7 M | 10.5 M | 15.3 M | 21.4 M | 10.1 M | 12.1 M | 12.1 M | 4.08 M | -868 K | 1.7 M |
Total Shareholders Equity |
6.14 M | 7.98 M | 8.7 M | 5.36 M | 5.62 M | 10.5 M | 15.3 M | 21.4 M | 10.1 M | 12.1 M | 12.1 M | 4.08 M | -868 K | 1.7 M |
All numbers in USD currency
Quarterly Balance Sheet Sonoma Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
46 K | 61 K | 87 K | 160 K | 134 K | 121 K | 162 K | 15 K | 15 K | 15 K | - | 362 K | - | - | 1.31 M | 1.31 M | 1.31 M | 1.31 M | 1.31 M | - | - | - | 12 K | 14 K | 25 K | 29 K | 32 K | 35 K | 39 K | 42 K | 45 K | 48 K | 50 K | - | - | - | - | - | - | - | - | 1 K | 4 K | 12 K | 519 K | 696 K | 676 K | 424 K | 1.09 M | 1.44 M | 1.82 M | 2.29 M | 1.7 M | 2.1 M | 1.64 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.33 M | 8.7 M | 8.6 M | 7.93 M | 7.96 M | 8.65 M | 8.25 M | 8.37 M | 7.94 M | 9.2 M | 10.1 M | 8.18 M | 8.37 M | 9.5 M | 9.62 M | 5.92 M | 6.58 M | 7.42 M | 7.24 M | 5.29 M | 5.87 M | 5.41 M | 3.96 M | 3.7 M | 3.56 M | 4 M | 3.88 M | 4.1 M | 3.99 M | 3.82 M | 4.03 M | 4.64 M | 3.2 M | 3.57 M | 3.66 M | 2.98 M | 2.84 M | 3.07 M | 2.99 M | 4.01 M | 5.02 M | 6.48 M | 8.73 M | 6.45 M | 7.33 M | 7.96 M | 8.48 M | 8.7 M | 13.9 M | 9.35 M | 8.71 M | 8.82 M | 7.9 M | 8.82 M | 6.96 M |
Deferred Revenue |
319 K | 413 K | 478 K | 75 K | 101 K | 100 K | 100 K | 100 K | 100 K | 100 K | 1.22 M | 100 K | 100 K | 185 K | 267 K | 150 K | 150 K | 150 K | 150 K | 228 K | 228 K | 228 K | 47 K | 174 K | 186 K | 139 K | 147 K | 180 K | 199 K | 285 K | 345 K | 794 K | 651 K | 656 K | 274 K | 456 K | 391 K | 507 K | 769 K | 1.56 M | 1.99 M | 2.25 M | 2.63 M | 2.66 M | 2.32 M | 2.28 M | 2.32 M | 2.87 M | 2.87 M | 1.63 M | 1.62 M | 1.85 M | 1.9 M | 1.88 M | 1.81 M |
Retained Earnings |
-196 M | -195 M | -194 M | -193 M | -192 M | -191 M | -190 M | -188 M | -186 M | -185 M | -184 M | -181 M | -180 M | -180 M | -179 M | -173 M | -172 M | -172 M | -171 M | -171 M | -170 M | -169 M | -169 M | -166 M | -164 M | -161 M | -157 M | -153 M | -149 M | -147 M | -143 M | -141 M | -157 M | -155 M | -152 M | -149 M | -146 M | -145 M | -142 M | -141 M | -135 M | -134 M | -134 M | -141 M | -141 M | -139 M | -138 M | -135 M | -133 M | -132 M | -132 M | -131 M | -128 M | -127 M | -125 M |
Total Assets |
13.7 M | 13.7 M | 14.7 M | 14.6 M | 13.6 M | 15.9 M | 16.2 M | 13.9 M | 15 M | 17.2 M | 18.8 M | 19.3 M | 19.8 M | 14.1 M | 15 M | 18.2 M | 18.1 M | 18.1 M | 18.7 M | 16.5 M | 16.1 M | 16.9 M | 14.4 M | 17 M | 14.3 M | 16.6 M | 19.2 M | 18.4 M | 20.2 M | 22.4 M | 25.5 M | 27.5 M | 9.24 M | 11.3 M | 13.8 M | 12.1 M | 13.6 M | 14.2 M | 15 M | 11.8 M | 18.4 M | 19.9 M | 20.8 M | 9.84 M | 8.88 M | 10.6 M | 12.6 M | 11.8 M | 13.4 M | 9.69 M | 7.84 M | 8.98 M | 7.76 M | 9.21 M | 8.66 M |
Cash and Cash Equivalents |
4.08 M | 2.59 M | 3.13 M | 2.41 M | 2.14 M | 3.54 M | 3.82 M | 2.63 M | 3.35 M | 5.59 M | 7.4 M | 8.53 M | 8.39 M | 2.81 M | 4.22 M | 5.54 M | 5.54 M | 4.32 M | 4.55 M | 3.73 M | 3.73 M | 3.23 M | 4.28 M | 6.5 M | 6.5 M | 4.05 M | 10.1 M | 8.62 M | 9.98 M | 12.6 M | 17.5 M | 19 M | 3.25 M | 4.97 M | 7.47 M | 6.11 M | 7.97 M | 8.75 M | 6.14 M | 2.24 M | 3.55 M | 4.99 M | 5.48 M | 3.44 M | 3.19 M | 5.38 M | 7.9 M | 6.6 M | 8.31 M | 4.4 M | 3.35 M | 4.96 M | 3.62 M | 5.02 M | 4.37 M |
Book Value |
5.35 M | 4.98 M | 6.14 M | 6.69 M | 5.68 M | 7.24 M | 7.98 M | 5.56 M | 7.02 M | 7.96 M | 8.7 M | 11.2 M | 11.5 M | 4.62 M | 5.36 M | 12.3 M | 11.6 M | 10.7 M | 11.4 M | 11.2 M | 10.3 M | 11.5 M | 10.5 M | 13.3 M | 10.8 M | 12.6 M | 15.3 M | 14.3 M | 16.2 M | 18.6 M | 21.4 M | 22.9 M | 6.04 M | 7.75 M | 10.1 M | 9.12 M | 10.7 M | 11.1 M | 12.1 M | 7.83 M | 13.4 M | 13.4 M | 12.1 M | 3.4 M | 1.55 M | 2.62 M | 4.08 M | 3.13 M | -501 K | 342 K | -868 K | 163 K | -136 K | 387 K | 1.7 M |
Total Shareholders Equity |
5.35 M | 4.98 M | 6.14 M | 6.69 M | 5.68 M | 7.24 M | 7.98 M | 5.56 M | 7.02 M | 7.96 M | 8.7 M | 11.2 M | 11.5 M | 4.62 M | 4.62 M | 12.3 M | 12.3 M | 11.6 M | 10.7 M | 11.2 M | 11.2 M | 10.3 M | 11.5 M | 13.3 M | 13.3 M | 10.8 M | 15.3 M | 14.3 M | 16.2 M | 18.6 M | 21.4 M | 22.9 M | 6.04 M | 7.75 M | 10.1 M | 9.12 M | 10.7 M | 11.1 M | 12.1 M | 7.83 M | 13.4 M | 13.4 M | 12.1 M | 3.4 M | 1.55 M | 2.62 M | 4.08 M | 3.13 M | -501 K | 342 K | -868 K | 163 K | -136 K | 387 K | 1.7 M |
All numbers in USD currency